Talacotuzumab is used to inhibit IL-3 binding to CD123, thereby antagonizing IL-3 signaling in target cells; it enhances antibody-dependent cell-mediated cytotoxicity (ADCC) through Fc region mutations that increase affinity for CD16 (FcγRIIIa); it effectively reduces leukemia cell growth in acute myeloid leukemia (AML) xenograft mouse models.